AI Article Synopsis
- Meningiomas, common tumors in the central nervous system, can have HER-2/neu gene amplification, which may influence patient prognosis.
- The study analyzed tissue samples from 55 meningioma patients operated on between 1999 and 2002 using fluorescent in situ hybridization (FISH) to detect HER-2/neu gene copy numbers.
- Results revealed HER-2/neu gene amplification in 12.73% of patients, suggesting it could be a significant genetic factor in meningioma development alongside other chromosomal anomalies.
Article Abstract
Aim: Meningiomas arise from the meningoendothelial cells and are one of the most common tumors of the central nervous system. The HER-2/neu gene is located on the 17q11.2-q12 chromosome region and encodes an epidermal growth factor receptor. HER- 2/neu gene amplification and/or over expression have been studied most widely in breast carcinomas. Previous studies have shown the importance of HER-2/neu gene amplification on the prognosis of meningioma cases. In this study, we aimed to detect HER-2/neu gene copy number in archive materials of 55 meningioma patients by fluorescent in situ hybridization (FISH).
Material And Methods: The patients included in the study had undergone surgery in the neurosurgery department of our hospital between 1999 and 2002. Tissue samples were classified histologically according to WHO 2007 guidelines. Interphase FISH was performed on 3 to 4microm thick paraffin embedded tissue sections for the detection of HER- 2/neu gene amplification status.
Results: We found HER-2/neu gene amplification in 7 (12.73%) patients. Another 2 patients had only one signal for the HER-2/neu region. We confirmed this finding by a second hybridization with the chromosome 17p13.1 (p53) probe.
Conclusion: According to our results, HER-2/neu amplification could be regarded as an additional genetic factor playing role in meningioma pathogenesis together with known chromosomal abnormalities.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Dehydroevodiamine Alleviates Doxorubicin-Induced Cardiomyocyte Injury by Regulating Neuregulin-1/ErbB Signaling.
Cardiovasc Ther
January 2025
Department of Cardiothoracic Surgery, Ningbo Medical Center Lihuili Hospital of Ningbo University, No. 57, Xingning Rd, Ningbo City 315041, Zhejiang Province, China.
Doxorubicin (DOX) is a widely used antitumor drug; however, its use is limited by the risk of serious cardiotoxicity. Dehydroevodiamine (DHE) is a quinazoline alkaloid which has antiarrhythmic effects. The aim of this study was to investigate the protective effect of DHE on doxorubicin-induced cardiotoxicity (DIC) and its potential mechanism.
View Article and Find Full Text PDFCharacterization of breast cancer tumors in older patients who show de novo resistance to endocrine therapy.
Sci Rep
December 2024
Department of Breast Oncology, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
The standard treatment for hormone receptor-positive breast cancer in good general condition is curative surgery followed by endocrine therapy. However, for older patients, endocrine therapy alone is sometimes chosen instead of curative surgery due to health conditions or personal preference, though this is not yet a standard approach. It is crucial to develop elderly-specific treatment strategies, potentially establishing endocrine therapy alone as a standard option.
View Article and Find Full Text PDFPotential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors.
Int J Mol Sci
November 2024
Computational Genomics Division, National Institute of Genomic Medicine, Mexico City 14610, Mexico.
HER2-positive (HER2+) breast cancer is characterized by the overexpression of the ERBB2 (HER2) gene, which promotes aggressive tumor growth and poor prognosis. Targeting the ERBB2 pathway with single-agent therapies has shown limited efficacy due to resistance mechanisms and the complexity of gene interactions within the tumor microenvironment. This study aims to explore potential drug synergies by analyzing gene-drug interactions and combination therapies that target the ERBB2 pathway in HER2+ breast tumors.
View Article and Find Full Text PDFGenomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.
Signal Transduct Target Ther
December 2024
Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
Article Synopsis
- The study analyzed data from 1071 metastatic breast cancer patients to explore the characteristics and treatment impacts of those with HER2-low status, emphasizing the need for improved clinical guidance in this population.
- Key mutations found in HER2-low patients include TP53, PIK3CA, and ESR1, which are linked to metabolic changes and could influence treatment responses.
- Results indicate that while HER2-low and HER2-0 patients generally respond similarly to standard treatments, those with specific genetic mutations may benefit more from personalized approaches, supporting the development of tailored treatment strategies based on tumor characteristics.
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers.
Breast Cancer Res
December 2024
Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Article Synopsis
- Researchers focused on breast cancer subtypes Luminal A and Luminal B, using machine learning to analyze H&E images, aiming to identify tumor characteristics linked to higher recurrence risks.
- The study involved training models on segmented images of tumors, finding that an image-based protocol effectively predicted recurrence times, comparable to traditional genomic testing methods (PAM50).
- Results indicated that while adjusting for tumor grade didn't significantly improve subtype prediction, the image analysis provided a viable alternative in identifying patients in need of genomic testing, potentially increasing testing rates among ER+/HER2-patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!